Inkef

Draupnir Bio is focused on developing innovative cholesterol-lowering medications that aim to prevent heart blood clots more effectively than existing treatments. The company leverages a platform technology that explores the glycome to create novel therapeutics through advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. Draupnir Bio specializes in synthesizing, screening, and selecting potent heparan sulfate glycomimetic drug candidates that address cardiovascular, inflammatory, and infectious diseases. Additionally, the company is working on protein degraders that target extracellular disease proteins, which could potentially address a wide range of unmet therapeutic needs across various medical conditions, providing more convenient treatment options compared to traditional injectable therapies.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Provable Markets is a financial services company that offers market participants a secure, unified, and pragmatic access point for cash and synthetic equity finance trading. The company has developed an SEC registered Alternative Trading System (ATS) named Aurora. Provable Markets aims to create a paradigm shift in how financial markets operate, with a focus on transparency and solving some of the biggest challenges in the financial industry. The company has a community of passionate people working towards these goals.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Silverflow is a payment processing technology company that offers a cloud-based platform enabling direct access to card networks for payment service providers (PSPs). Founded in 2019 and headquartered in Amsterdam, the company enhances the capabilities of PSPs by allowing them to add new functionalities instantly and gain real-time insights into transaction fees. Silverflow's platform simplifies card-acquiring processing as a service, providing smart data and a streamlined data flow through application programming interfaces. This innovation promotes agility, transparency, and security in global payment operations, ultimately improving service for merchants.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Anavo Therapeutics is a pioneering company focused on drugging phosphatases, a category of targets that has been deemed undruggable for many years. By leveraging world-class scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo aims to develop innovative therapeutic programs, particularly in oncology. The company is advancing multiple first-in-class therapies and seeks to establish a robust pipeline across various indications through strategic partnerships. Anavo's work in this area seeks to unlock the potential of phosphatase-targeted allosteric modulators, offering new avenues for treatment in diseases where traditional approaches have fallen short.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

Happeo is a digital workplace platform that enables organizations to streamline knowledge management and internal communication in a cohesive environment. The platform features a template-based page builder, allowing for easy customization and scalability to accommodate companies of various sizes. Happeo integrates seamlessly with existing company tools, facilitating universal search capabilities that enhance productivity. Prominent organizations, such as Doctolib, GANT, and Marqeta, utilize Happeo to keep their teams informed and aligned. The platform supports a range of functions, including calendar management, file sharing, conferencing, and project oversight, while also integrating with CRM and HR systems. By fostering engagement and enhancing the employee experience, Happeo is dedicated to helping organizations grow effectively.

Baserow is a no-code, open-source database platform founded in 2021 by Bram Wiepjes and Olivier Maes. It empowers non-technical teams to capture and organize data, facilitating the generation of intelligent business insights and the automation of processes. By providing tools for creating flexible checklists, managing customer contacts, and organizing ideas, Baserow enables users to build custom applications without any coding experience. The platform addresses common challenges associated with existing SaaS solutions, such as data governance, scalability, and security, allowing organizations to manage critical business processes more effectively.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

ChannelEngine is a cloud-based multichannel platform that facilitates seamless integration between sellers' systems and international marketplaces. By connecting webshops with various e-commerce platforms, ChannelEngine enables brands, distributors, and retailers to automate their sales processes, including order and returns management. The platform is designed to optimize sales performance while minimizing operational time, thereby enhancing profitability and market reach. With an advanced management suite and a rich partner ecosystem, ChannelEngine empowers businesses to fully leverage their international sales potential.

Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at the genetic level.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Ambagon Therapeutics is a biotechnology company focused on developing small-molecule therapeutics for cancer treatment. The company specializes in research aimed at stabilizing the interactions of oncogenic proteins, which are often difficult to modulate with traditional methods. By selectively enhancing the activity of tumor-suppressing proteins associated with transcription factors and oncoproteins, Ambagon aims to provide new therapeutic options for addressing significant unmet clinical needs in oncology. Founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin, the company is dedicated to advancing innovative solutions in cancer care.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Silverflow is a payment processing technology company that offers a cloud-based platform enabling direct access to card networks for payment service providers (PSPs). Founded in 2019 and headquartered in Amsterdam, the company enhances the capabilities of PSPs by allowing them to add new functionalities instantly and gain real-time insights into transaction fees. Silverflow's platform simplifies card-acquiring processing as a service, providing smart data and a streamlined data flow through application programming interfaces. This innovation promotes agility, transparency, and security in global payment operations, ultimately improving service for merchants.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Urban Sports Club is a Berlin-based company founded in 2012 by Moritz Kreppel and Benjamin Roth, focused on promoting healthy and active lifestyles through a flexible sports membership model. It offers access to over 50 different sports activities, including gym workouts, swimming, yoga, and team sports, available at more than 10,000 partner venues across Germany, France, Italy, Spain, Portugal, and Belgium. The company targets both individuals and corporate clients, allowing members to enjoy a diverse range of wellness and fitness options. Following its initial bootstrapping phase, Urban Sports Club expanded through strategic acquisitions of several German competitors, including Somuchmore, FITrate, INTERFIT, and OneFit, enhancing its service offerings and market presence. The company's innovative approach aims to reinvent the leisure and corporate sports market by providing a comprehensive and convenient sports experience for its members.

Sentinels is an AI-powered startup specializing in transaction monitoring solutions for the financial industry. The company offers a cloud-based platform that enhances compliance efforts for fintech companies by providing data-driven insights to combat money laundering and other illegal activities. By optimizing anti-money laundering processes, Sentinels enables compliance experts to gain real-time, actionable information, thereby improving the effectiveness of their monitoring efforts.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Anavo Therapeutics is a pioneering company focused on drugging phosphatases, a category of targets that has been deemed undruggable for many years. By leveraging world-class scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo aims to develop innovative therapeutic programs, particularly in oncology. The company is advancing multiple first-in-class therapies and seeks to establish a robust pipeline across various indications through strategic partnerships. Anavo's work in this area seeks to unlock the potential of phosphatase-targeted allosteric modulators, offering new avenues for treatment in diseases where traditional approaches have fallen short.

Lengoo is a technology company that specializes in unlocking the potential of language data for enterprises. Its full-stack technology, HALOS, enables organizations to build and operate custom language models at scale while maintaining high standards of IT security and intellectual property protection. For over five years, Lengoo has been assisting global industry leaders, hidden champions, and scale-ups in securely adopting AI solutions. The company's language intelligence applications, such as Flow, along with a robust API, empower office workers by providing them with trusted virtual AI partners. This enhances organizational efficiency and supports ongoing growth.

ChannelEngine is a cloud-based multichannel platform that facilitates seamless integration between sellers' systems and international marketplaces. By connecting webshops with various e-commerce platforms, ChannelEngine enables brands, distributors, and retailers to automate their sales processes, including order and returns management. The platform is designed to optimize sales performance while minimizing operational time, thereby enhancing profitability and market reach. With an advanced management suite and a rich partner ecosystem, ChannelEngine empowers businesses to fully leverage their international sales potential.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Silverflow is a payment processing technology company that offers a cloud-based platform enabling direct access to card networks for payment service providers (PSPs). Founded in 2019 and headquartered in Amsterdam, the company enhances the capabilities of PSPs by allowing them to add new functionalities instantly and gain real-time insights into transaction fees. Silverflow's platform simplifies card-acquiring processing as a service, providing smart data and a streamlined data flow through application programming interfaces. This innovation promotes agility, transparency, and security in global payment operations, ultimately improving service for merchants.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Happeo is a digital workplace platform that enables organizations to streamline knowledge management and internal communication in a cohesive environment. The platform features a template-based page builder, allowing for easy customization and scalability to accommodate companies of various sizes. Happeo integrates seamlessly with existing company tools, facilitating universal search capabilities that enhance productivity. Prominent organizations, such as Doctolib, GANT, and Marqeta, utilize Happeo to keep their teams informed and aligned. The platform supports a range of functions, including calendar management, file sharing, conferencing, and project oversight, while also integrating with CRM and HR systems. By fostering engagement and enhancing the employee experience, Happeo is dedicated to helping organizations grow effectively.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Remote is a global HR solutions provider that facilitates international hiring and payroll management for distributed teams. They offer a platform designed to help companies recruit top talent worldwide, ensuring compliance with local laws while streamlining project allocation and payments. This enables businesses to expand their workforce globally, enhancing productivity and employment opportunities.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Draupnir Bio is focused on developing innovative cholesterol-lowering medications that aim to prevent heart blood clots more effectively than existing treatments. The company leverages a platform technology that explores the glycome to create novel therapeutics through advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. Draupnir Bio specializes in synthesizing, screening, and selecting potent heparan sulfate glycomimetic drug candidates that address cardiovascular, inflammatory, and infectious diseases. Additionally, the company is working on protein degraders that target extracellular disease proteins, which could potentially address a wide range of unmet therapeutic needs across various medical conditions, providing more convenient treatment options compared to traditional injectable therapies.

Cashforce BV, established in 2013, is a Belgian company with offices in Antwerp, New York, Amsterdam, Copenhagen, and London. It specializes in a smart cash flow management and forecasting platform, enabling users to predict cash inflows and outflows across multiple companies, bank accounts, and currencies. The platform integrates seamlessly with various ERPs and banking systems, providing detailed transaction-level insights and AI-based cash flow scenario simulations. Cashforce serves multinational corporations across diverse industries in over 120 countries, empowering CFOs, finance teams, and treasury departments to enhance cash visibility, optimize working capital, and make data-driven decisions.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Urban Sports Club is a Berlin-based company founded in 2012 by Moritz Kreppel and Benjamin Roth, focused on promoting healthy and active lifestyles through a flexible sports membership model. It offers access to over 50 different sports activities, including gym workouts, swimming, yoga, and team sports, available at more than 10,000 partner venues across Germany, France, Italy, Spain, Portugal, and Belgium. The company targets both individuals and corporate clients, allowing members to enjoy a diverse range of wellness and fitness options. Following its initial bootstrapping phase, Urban Sports Club expanded through strategic acquisitions of several German competitors, including Somuchmore, FITrate, INTERFIT, and OneFit, enhancing its service offerings and market presence. The company's innovative approach aims to reinvent the leisure and corporate sports market by providing a comprehensive and convenient sports experience for its members.

Comet Therapeutics, established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing novel small-molecule treatments for various diseases, with a focus on orphan neurological disorders. The company's core technology is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism, thereby addressing significant unmet medical needs in these areas.

Withlocals is a global marketplace founded in 2013 that specializes in personalized travel experiences through private tours and activities led by local hosts. Offering over 1,200 fully customizable options in numerous international cities, Withlocals connects travelers with approximately 900 verified local hosts, allowing for authentic cultural experiences tailored to individual interests such as food, music, and sports. The platform seeks to provide an affordable alternative to traditional tourism by facilitating direct communication between hosts and travelers, enabling users to explore destinations off the beaten path. Withlocals aims to foster connections between people and cultures, enhancing the overall travel experience.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.

Aidence is a company focused on developing AI-powered clinical applications aimed at enhancing the diagnosis and management of lung cancer. Utilizing a team of over 80 experts in data science, software engineering, and medical fields, Aidence has created Veye Lung Nodules, a solution specifically designed for the management of pulmonary nodules detected in CT scans. This application is actively used in routine clinical practice and lung cancer screening programs across Europe. By transforming complex data into practical insights, Aidence's platform aids physicians in improving patient outcomes through faster diagnosis, reduced risk of misdiagnosis, and early detection of lung cancer.

GeoPhy is a developer of an artificial intelligence-based property analytics platform that enhances the commercial real estate sector by providing instant and accurate property valuations. The company leverages a combination of traditional and alternative data sources, along with machine learning, to deliver insights that help real estate professionals understand property values and the factors influencing them. By sizing market opportunities according to specific criteria and offering comprehensive property overviews, GeoPhy aims to make commercial real estate more transparent, efficient, and responsive. Its solutions assist clients in identifying opportunities and managing risks, thereby streamlining decision-making within the industry.

Polarsteps is a travel tracking platform that allows users to plan, document, and share their journeys in an engaging manner. The app automatically records the routes and locations traveled while users are on the move, creating a real-time account of their adventures. Once online, the app syncs this information, including key locations and photos, to the user's Polarsteps page. This page displays the travel route on a colorful world map and can be shared with friends and family, enabling travelers to preserve their experiences and create personal photo albums. By offering an intuitive and visually appealing way to track trips, Polarsteps enhances the travel experience and helps users cherish their memories.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

OneFit is a fitness aggregator that offers users access to a wide variety of gyms and studios through a single monthly membership. This all-in-one sports membership allows individuals to explore different fitness options, including various workout classes and training environments, without the need for multiple subscriptions. By streamlining the fitness experience, OneFit caters to a diverse clientele seeking flexibility and convenience in their workout routines.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Health Value Creation is developing two surgical devices, a diagnostic tool and a trocar closure device. The first device helps prevent anastomotic leakages after bowel surgery by predicting the quality of the anastomosis during surgery, thereby reducing post-operative complications and lowering healthcare costs. The second device is a trocar closure device for faster, safer and more secure suturing after laparoscopic surgery, resulting in a reduction of the chances of wound herniation.

Withlocals is a global marketplace founded in 2013 that specializes in personalized travel experiences through private tours and activities led by local hosts. Offering over 1,200 fully customizable options in numerous international cities, Withlocals connects travelers with approximately 900 verified local hosts, allowing for authentic cultural experiences tailored to individual interests such as food, music, and sports. The platform seeks to provide an affordable alternative to traditional tourism by facilitating direct communication between hosts and travelers, enabling users to explore destinations off the beaten path. Withlocals aims to foster connections between people and cultures, enhancing the overall travel experience.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at the genetic level.

Blendle is a digital media platform that allows readers to purchase articles from various Dutch and Belgian newspapers and magazines, including prominent publications like the Economist. Users can buy individual articles for prices ranging from €0.10 to €0.30, and they are presented with a selection of recommendations similar to social media feeds. New users are provided with an initial credit of €2.50 to explore the platform. The service includes a brief refund window for article purchases, after which Blendle retains a 30% commission on sales. By offering a pay-per-article model, Blendle aims to enhance access to quality journalism and cater to readers' preferences through personalized recommendations.

Bloomon B.V. is an online retail company based in Amsterdam, Netherlands, specializing in the direct delivery of quality flowers to consumers across Europe. Founded in 2014, Bloomon operates a platform that connects customers directly with flower growers, ensuring freshness and quality. The company emphasizes customer service and offers a subscription model, allowing clients to easily arrange, pause, change, or cancel their orders without commitment. This approach enables users to customize their flower packaging and enjoy a tailored experience, focusing on delivering not just products but also a unique service.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

GeoPhy is a developer of an artificial intelligence-based property analytics platform that enhances the commercial real estate sector by providing instant and accurate property valuations. The company leverages a combination of traditional and alternative data sources, along with machine learning, to deliver insights that help real estate professionals understand property values and the factors influencing them. By sizing market opportunities according to specific criteria and offering comprehensive property overviews, GeoPhy aims to make commercial real estate more transparent, efficient, and responsive. Its solutions assist clients in identifying opportunities and managing risks, thereby streamlining decision-making within the industry.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Crowdynews is a technology company that specializes in an artificial intelligence-driven social media curation platform designed for the news media market. The platform automates the integration of real-time, relevant, and safe social content from various sources, including Twitter, Facebook, Instagram, YouTube, and Vimeo, alongside traditional editorial content. By leveraging AI and natural language processing, Crowdynews enables its clients, which include news organizations and consumer brands, to enhance their storytelling capabilities. This service allows users to incorporate diverse media, such as photos, videos, eyewitness reports, and social opinions, thereby driving audience engagement, improving conversion rates, and expanding reach. Ultimately, Crowdynews aims to create more valuable connections between content creators and consumers, enabling a more comprehensive narrative.

Wercker is a software company that provides a platform and tools to streamline the development, building, and deployment of containerized applications and microservices for modern cloud environments. Their solution aims to simplify and accelerate the software development lifecycle, enabling businesses and developers to achieve continuous integration and continuous delivery (CI/CD) goals.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.

Audion Therapeutics BV is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for ear-related diseases, particularly hearing loss. Established in 2008 and headquartered in Amsterdam, the Netherlands, the company concentrates on small molecule drug discovery aimed at regenerating inner hair cells, which are crucial for hearing. Audion Therapeutics is developing therapies that target the gamma-secretase protein complex to restore auditory function, addressing sensorineural hearing loss often associated with aging. The company's intellectual property portfolio encompasses novel molecules, advanced delivery systems, and drug discovery tools specifically designed for hearing loss research.

Bloomon B.V. is an online retail company based in Amsterdam, Netherlands, specializing in the direct delivery of quality flowers to consumers across Europe. Founded in 2014, Bloomon operates a platform that connects customers directly with flower growers, ensuring freshness and quality. The company emphasizes customer service and offers a subscription model, allowing clients to easily arrange, pause, change, or cancel their orders without commitment. This approach enables users to customize their flower packaging and enjoy a tailored experience, focusing on delivering not just products but also a unique service.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

Crowdynews is a technology company that specializes in an artificial intelligence-driven social media curation platform designed for the news media market. The platform automates the integration of real-time, relevant, and safe social content from various sources, including Twitter, Facebook, Instagram, YouTube, and Vimeo, alongside traditional editorial content. By leveraging AI and natural language processing, Crowdynews enables its clients, which include news organizations and consumer brands, to enhance their storytelling capabilities. This service allows users to incorporate diverse media, such as photos, videos, eyewitness reports, and social opinions, thereby driving audience engagement, improving conversion rates, and expanding reach. Ultimately, Crowdynews aims to create more valuable connections between content creators and consumers, enabling a more comprehensive narrative.

Aito is a technology company specializing in the development and provision of electronic products and solutions that incorporate touch sensations. Their core technology, Piezo Sensing and Haptics, is patented and award-winning, enabling surfaces to respond with tactile feedback. This innovation allows consumer electronics brands to differentiate their products in competitive markets by offering enhanced user experiences. Aito's offerings include configurable integrated circuits for various touch interfaces, such as buttons, touchpads, and touch screens, catering to a wide range of client needs.

NPEX is a company that operates a secure online trading platform designed to facilitate connections between entrepreneurs seeking financing and investors looking for returns. The platform enables clients to trade securities, including stocks and bonds, while offering features such as interest on bonds and access to clear, comprehensive documentation for investors. Additionally, NPEX enhances brand visibility for entrepreneurs through media exposure, thereby supporting their fundraising efforts. The company's focus is on creating a transparent and efficient environment for both companies and investors in the financial markets.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, focused on the discovery and development of novel lantipeptide drugs targeting serious medical conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. Founded in 2010, the company leverages its proprietary LanthioPep technology to create peptide therapeutics that exhibit enhanced resistance to degradation, high specificity for receptors, and improved intrinsic activity. Among its key products are LP2, a selective angiotensin II type 2 receptor agonist aimed at treating fibrosis; PanCyte, designed for ischemic stroke recovery and peripheral vascular disease; and a lanthi-apelin agonist targeting the APJ receptor, which plays a role in various organ systems. Lanthio Pharma is committed to advancing therapeutic options for patients suffering from these severe diseases.

NPEX is a company that operates a secure online trading platform designed to facilitate connections between entrepreneurs seeking financing and investors looking for returns. The platform enables clients to trade securities, including stocks and bonds, while offering features such as interest on bonds and access to clear, comprehensive documentation for investors. Additionally, NPEX enhances brand visibility for entrepreneurs through media exposure, thereby supporting their fundraising efforts. The company's focus is on creating a transparent and efficient environment for both companies and investors in the financial markets.

Robin Radar Systems B.V. is a company based in The Hague, Netherlands, specializing in advanced bird detection systems that monitor bird movements to enhance safety and operational efficiency. The company offers several radar systems, including the 2D Mobile system, which detects the presence, location, direction, speed, and route of birds up to 20 kilometers away; the 3D Fixed system, which provides similar data for heights up to 10 kilometers; and the 3D Flex system that combines horizontal S-band radar with flexible frequency modulation. Additionally, Robin Radar Systems offers the Military XL, designed to assist air forces in preventing bird strikes. Established in 2010 as a spin-off from the Dutch Research Institute for Applied Science, the company has exclusive access to advanced bird radar technology developed since the 1970s. Robin Radar Systems is committed to delivering high-quality technology and comprehensive support services, ensuring their solutions effectively meet client needs in various sectors such as aviation, wind energy, and environmental research.

ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.